Versatope Therapeutics is a clinical stage biotech using its proprietary bacterial extracellular vesicle (bEV) technology to deliver vaccines and immunotherapeutics. This breakthrough technology elicits robust immune responses, eliminates cold chain dependency, and simplifies production. Versatope’s lead asset, a universal flu A vaccine, has shown stronger and longer-lasting immunity compared to current flu vaccines in preclinical studies. With the potential to revolutionize vaccine development, immunotherapy, and precision drug delivery, Versatope will enter Phase 1 clinical studies in 2025.
MassBio Member Spotlight: Versatope Therapeutics
Location: Lowell, MA
Website: versatope.com
Leadership:
- Christopher Locher, PhD | CEO
- M. P. Anza Mammen, MD | CMO
- Alan Barber, CPA | CFO
- Kumkum Saxena, PhD | Head of Preclinical Research
Therapeutic Area: Universal Influenza Vaccine